SolAcne - A Manufacturer of Dermatological Cosmetics Releases Full Anti-Acne

Protection Set in Europe

Düsseldorf, Germany, January 12, 2021 --(PR.com)-- SolAcne is a manufacturer and distributor of
dermatological cosmetics intended to treat acne. It's one of the most successfully developing companies
in the branch on the European market.

SolAcne full anti-acne protection set consists of two products - SolAcne wash gel and SolAcne active
cream, that can be purchased separately or together depending on client's needs.

SolAcne wash gel is formulated to cleanse the skin, tighten the pores, provide oil-free but well-hydrated
skin and regulate the sebum production.

SolAcne active cream is intended to remove blackheads, whiteheads, and pimples and to hydrate and
soften the skin.

The active ingredients in the SolAcne set are Nordihydroguaiaretic acid (NDGA) and Oleanolic acid.
When mixed together, both acids work in synergy to effectively reduce the acne. The Oleanolic acid
reduces the production of excessive sebum, while the NDGA is a cell growth regulator that reduces
excessive build-up of skin cells and acts as a strong anti-inflammatory agent.

Designed for oily and problemtic skin and acneic skin with blackheads, the washing gel removes
impurities, reduces the excess sebum secretion, and provides long-lasting hydration without making the
skin oily. SolAcne cream, that should be used after cleansing the face with SolAcne gel, is additionally
enriched with Betula Alba leaf and Willow Bark extracts that stimulate cell regeneration, have
antioxidant properties, and reduce the risk of scarring caused by acne.

SolAcne offers discounts and special promotions and all who want to stay informed can check the official
website of the product.

Page 1/2
PR.com Press Release Distribution Terms of Use
Contact Information:
SolAcne
Hannah Thompson
718-666-5679
Contact via Email
https://www.solacne.com/

Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/828837

News Image:

Page 2/2
PR.com Press Release Distribution Terms of Use